EntreMed Reports Second Quarter 2009 Financial Results

...ers, multiple myeloma, and leukemia. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mtor pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced ca...

Teaming Up to Tackle a Deadly Cancer

...different groups presented new research on the involvement of the so-called mtor genetic pathway in chordomas. The findings led to a study in Italy treating chordoma patients with a drug called rapamycin that is active in the mtor pathway. Results published on July 1 in the Annals of Oncology demonstrat...

Study pinpoints novel cancer gene and biomarker

...hin notes, "suggesting the tumor-promoting effect of GOLPH3 is dependent on mtor signaling." Lastly, the team considered whether the same mechanism might... with too many copies of the GOLPH3 gene also had abnormally high levels of mtor activity. "The mechanistic relationship we'd identified in the mouse system...

Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position

...Welfare and the Pharmaceuticals and Medical Devices Agency. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mtor inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the c...

Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials

...Welfare and the Pharmaceuticals and Medical Devices Agency. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mtor inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the c...

2-drug combination appears safe and active in metastatic kidney cancer

...r investigators report that a two-drug blockade of mtor signaling appears safe in metastatic kidney cancer...ination may be active to some degree for them." mtor signaling promotes tumor cell proliferation and bl...isel), blocks signaling through one portion of the mtor signaling complex, called TORC1, and slows tumor p...

Two Drugs Safe for Rare Forms of Kidney Cancer

... 25 patients in a phase 1 trial. The researchers said a pathway known as mtor signaling promotes tumor cell proliferation and tumor blood vessel development. The temsirolimus-bryostatin combination blocks two portions of the mtor signaling pathway, and the early data suggests the drugs may be active in p...

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study

... part of a distribution agreement between the two companies. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mtor inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the c...

Abbott Announces EuroPCR 2009 Activities

...ss information, is available online at www.xiencev.com . Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mtor inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the c...

EntreMed Reports First Quarter 2009 Financial Results

...d multiple myeloma. In addition, multiple Phase 1 and 2 clinical trials are ongoing for MKC-1, an oral cell-cycle regulator with activity against the mtor pathway, and ENMD-1198, a novel tubulin-binding agent. The Company also has an approved IND application for Panzem(R) in the treatment of rheumatoid ...

mTOR in Medical Technology

Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycin's Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, presented first-time data from a pre-clinical study evaluating the toxicity and antitumor effect of nab-rapamycin (ABI-009), an albumin-bound mTOR kinase inhibitor, ...

Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 25, 2007 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical investigators from leading cancer centers will present Phase 2 and 1b clinical data from ongoing trials of the Company's novel mTOR inhibitor, AP23573, at the annual meeting of...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...or more information, please visit http://www.us.novartis.com . References Thomas E. Witzig et al. A Phase II Trial of the Oral mtor Inhibitor Everolimus in Relapsed Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). EHA 14th Congress. Berlin, Germany National Cance...

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...vanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mtor pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced ca...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

...d aberrant PI3K pathway activity is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream effectors AKT and mtor is also known to promote tumor cell survival, proliferation, and growth. Dysregulation of PI3K signaling is also thought to contribute resistance to ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

...eatment with both a VEGF Receptor Inhibitor and an mtor Inhibitor NEW YORK, May 29 /PRNewswire-Firs...receptor inhibitor (sunitinib or sorafenib) and an mtor inhibitor (either everolimus or temsirolimus). Fo... N (%) N (%) N (%) VEGF + mtor 16 1 (6%) 7 (44%) 8 (50%) 16 we...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...n. of the New York Acad of Sci. 2006 Jan 16 2005;1014:13-27. Chen L, et al. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mtor inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). Abstract # 4587. American Society of Clinical Oncology 2009 Annual Meeting,...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

...d aberrant PI3K pathway activity is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream effectors AKT and mtor is also known to promote tumor cell survival, proliferation, and growth. Notably, dysregulation of PI3K signaling is thought to contribute to resista...

Bionovo Announces First Quarter 2009 Highlights and Financial Results

...tive compound of BN108 that is responsible for BN108's selective cytotoxicity. BN108 and TspA3 induce apoptosis through rapid inactivation of AKT and mtor kinases in breast cancer cells but not in normal cells. Two additional members joined Bionovo's Scientific Advisory Board, Jan-Ake Gustafsson...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

...rowth. Preclinical and clinical data have established the important role of mtor in the development and progression of several types of tumors(1). "Wit...aily), the largest Phase III clinical trial to study the effects of an oral mtor inhibitor in advanced RCC patients whose cancer progressed despite prior tr...

mTOR in Biological News

KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex

Martinsried, Germany, April 29, 2009 / b3c newswire / - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-infla...

ASBMB Annual Meeting to feature talks on the biochemistry of aging

... billion years ago. They found a statistically significant connection in the genes and pathways that affect aging in both organisms, including reduced mtor signaling. They suggest that the conservation of aging genes across animals exists not because specific genes have evolved to regulate aging, but rath...

Progression of retinal disease linked to cell starvation

...t higher levels. Sleuthing revealed that 34.9 percent of those play a role in cellular metabolism, including 12 genes in the insulin/mTOR pathway. mtor serves as a signaling hub, gathering information about the environment and helping the cell to decide whether it has enough nutrients to make new prot...

How what and how much we eat (and drink) affects our risk of cancer

...also shown that dietary energy balance alters signaling through the Akt and mtor pathways, both of which are related to TPA-mediated skin tumor development....pose that the mechanism for the effect of dietary energy balance on Akt and mtor signaling may be mediated, in part, by changes in serum IGF-1 levels, which...

Genetic breakthrough offers promise in tackling kidney tumors

...and has been shown in the past to control the activity of a protein, mTOR, which is normally controlled by the TSC1 and TSC2 genes. If the genes fail, mtor is too active leading to tuberous sclerosis. The UK study tested the effects of Sirolimus on kidney tumours in patients with tuberous sclerosis and...

Unique dual target specificity of kinase inhibitor key for success against cancer

...nit of PI3 kinase and a downstream molecule called mtor that also plays a critical role in cell growth. Al...fective. Importantly, dual inhibition of p110á and mtor with a low dose of PI-103 elicited no drug-related...hese data suggest that combinatorial inhibition of mtor and p110á represents a safe and effective therapy ...

UCLA scientists uncover mechanism of response to targeted therapy

...ed at UCLA in prostate cancer patients and researchers knew it targeted the mtor protein. Previous studies also had shown that inhibitors of mtor also might inhibit HIF. "We theorized that by inhibiting mTOR, which co...

Scientists discover that widely available drug also helps fight kidney disease

...kidney cells, which results in the formation of thousands of cysts that eventually destroy the kidney. Fortunately, a highly effective inhibitor of mtor is well known. This drug, rapamycin, was originally discovered in the 1970s in soil from Easter Island. It is used for immunosuppression in kidney tra...

Researchers identify target for cancer drugs

...hat influences a cell's ability to expand in size. mtor has been widely studied as the target for the immunosuppressant drug rapamycin (in fact, mtor is an acronym for "mammalian target of rapamycin")...t in Sabatini's lab, discovered a new protein that mtor interacts with called rictor, but he wasn't yet su...

mTOR in Biological Technology

Sanofi-aventis Announces Second Quarter 2009 Results

...L4 monoclonal antibody developed for cancer XL147 (orally-administered PI3K inhibitor) and XL765 (orally-administered double PI3K and target mtor inhibitor), developed for cancer: sanofi-aventis has obtained an exclusive world license for both of these products, which were developed by the biote...

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

...vanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mtor pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced ca...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

...thesis that rapamycin is active only on mTORC1 and inhibition of mTORC2 by either Erlotinib or Perifosine is necessary to achieve complete shutdown of mtor signaling pathway. The following abstract was presented yesterday: Abstract 2822: Evidence implicating Bim activation/induction in po...

Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting

...he investigators examined the in vitro and in vivo oncolytic activity of reovirus against the mouse melanoma cell line B16.F10 in combination with the mtor inhibitor rapamycin. The investigators concluded that in vitro synergy between rapamycin and reovirus is only seen when rapamycin is administered afte...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

...eveloping therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mtor pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antim...

EntreMed to Present at the New York Society of Security Analysts Industry Conference

...veloping therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mtor pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antim...

Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award

... as part of a distribution agreement between the two companies. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mtor inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the c...

Bionovo Reports Second Quarter 2008 Financial Results

..., and induces cell death only in estrogen receptor negative breast cancer cells. BN108 induces cancer cell death by rapid inactivation of both AKT and mtor pathways in breast cancer cells, but not in normal cells. -- The Company participated in a number of studies that have further elucidated the mechan...

SuperGen Reports 2008 Second Quarter Financial Results

...bitor of the PIM kinases, inducing apoptosis and cell cycle arrest, thereby causing a reduction in phospho-BAD levels and enhancement of mtor inhibition in vitro. SGI-1776 induced significant tumor regression in MV-4-11 (AML) and MOLM-13 (AML) xenograft models. -- MP-470,...

Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent

... as part of a distribution agreement between the two companies. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mtor inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the c...

mTOR in Biological Products

Rabbit Anti-mTOR Monoclonal Antibody,, Clone ZMD.414 from Invitrogen

Description:...n: Synthetic peptide derived from an internal region of human mouse and rat mtor (Mammalian target of rapamycin FRAP RAFT1 RAPT1). Specificity: Specific for the human mtor protein. On Western blots it identifies the target band at ~235 kDa. Reac...
Company:Invitrogen

mTOR in Biological Definition

Cell growth

... they grow larger. Cell size regulation in mammals The protein mtor is a serine/threonine kinase that regulates translation and cell division. Nutrient availability influences mtor so that when cells are not able to grow to normal size they will not underg...

mTOR in Biological Dictionary

Cell metabolism

...Cell • Chemistry & Biology • Current Biology ... Information on the mtor signaling pathway (mammalian target of rapamycin) and mtor inhibition as a ... tumor angiogenesis, and abnormal cell metabolism ...